CAMP4 Therapeutics received regulatory clearance in Australia and Argentina to begin a Phase 1/2 tri

New woodsy-themed family area will feature nine attractions, including the Midwest's longest, talles

Proceeds of $50.1 million will be used to support the Company's advancement of CMP-002 for the treat

Gainers Universe Pharmaceuticals (NASDAQ:UPC) shares increased by 108.5% to $6.59 during Monday&#39

Achieving Key Regulatory Milestone and Positioning the Company for its Next Phase of Growth Vancouve

Planned first-in-human clinical trial to assess a disease modifying intervention for patients with S

Planned first-in-human clinical trial to assess a disease modifying intervention for patients with S

Gainers Zhengye Biotechnology (NASDAQ:ZYBT) shares moved upwards by 24.0% to $1.71 during Wednesday

Gainers Advanced Biomed (NASDAQ:ADVB) shares rose 24.1% to $6.24 during Monday's pre-market ses

CAMBRIDGE, Mass. , July 17, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the

AYTU, CAMP and CRC have been added to the Zacks Rank #5 (Strong Sell) List on July 16, 2026.

CAMBRIDGE, Mass. , June 19, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the

Top analysts changed ratings on top names, including Sunrun, enGene Therapeutics, Camp4 Therapeutics

Top analysts upgraded XOM, CAMP, EXR, WPC, and KRC stocks, with price targets ranging from $44 to $1

Live demo listening session to approve artists onto the platform in real time New “golden ticket” su

JP Morgan analyst Anupam Rama upgrades Camp4 Therapeutics (NASDAQ:CAMP) from Neutral to Overweigh

Chardan Capital analyst Keay Nakae initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a

Canadian GoldCamps says Mercator resampling returned gold in 82% of samples, confirming mineralizati

Company to advance NI 43-101 Technical Report; 2026 exploration campaign to follow up on promising h

CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the C

CMP-002 administration resulted in a statistically significant improvement in seizure phenotypes and

CAMP4 Therapeutics Corporation (CAMP) came out with a quarterly loss of $0.32 per share versus the Z

Camp4 Therapeutics (NASDAQ:CAMP) reported quarterly losses of $(0.32) per share which missed the ana

Submitted first clinical trial regulatory filing for CMP-002 in Australia, with additional global re

Using epigenomic mapping and regulatory RNA (regRNA) Capture-seq, CAMP4 has assembled what it believ

Using epigenomic mapping and regulatory RNA (regRNA) Capture-seq, CAMP4 has assembled what it believ

Vancouver, British Columbia – TheNewswire - April 21, 2026 – Canadian GoldCamps Corp. (CSE: CAMP) (O

CAMBRIDGE, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the

Rodman & Renshaw analyst Seema Sheoran initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP)

Wall Street analysts changed outlook on top names. See complete view of rating changes, including up

Leerink Partners analyst Mani Foroohar maintains Camp4 Therapeutics (NASDAQ:CAMP) with a Outperfo

Camp4 Therapeutics (NASDAQ:CAMP) reported quarterly losses of $(0.87) per share which missed the ana

CAMP4 signs ASO collaboration with GSK, securing $17.5 million upfront as analysts reaffirm Outperfo

Collaboration to leverage CAMP4's RAP Platform® to accelerate development of novel antisense oli

CAMP4 Therapeutics Corporation ("CAMP4" or the "Company") (NASDAQ:CAMP), a clinical-

Camp4 Therapeutics (NASDAQ:CAMP) reported quarterly losses of $(0.55) per share which beat the analy

Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP)

Piper Sandler analyst Edward Tenthoff maintains Camp4 Therapeutics (NASDAQ:CAMP) with a Overweigh

Oversubscribed Financing led by Coastlands Capital with participation from new and existing investor